Acuitas Small Cap Active ETF (AIMS) Stock Price

24.0437 ▲ +0.1123 (+0.47%)
Open: 24.0199 Vol: 2.49K Day's range: 23.88 - 24.06 Apr 02, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
AIMS Technical Analysis
5 mins 30 mins Hourly Daily Weekly
NEUTRAL NEUTRAL NEUTRAL BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 N/A     N/A     N/A     23.63▲ 23.53▲
MA10 N/A     N/A     N/A     23.64▲ N/A    
MA20 N/A     N/A     N/A     23.67▲ N/A    
MA50 N/A     N/A     N/A     N/A     N/A    
MA100 N/A     N/A     N/A     N/A     N/A    
MA200 N/A     N/A     N/A     N/A     N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD N/A     N/A     N/A     N/A     N/A    
RSI N/A     N/A     N/A     51.232▲ N/A    
STOCH N/A     N/A     N/A     60.937     N/A    
WILL %R N/A     N/A     N/A     -1.552▲ N/A    
CCI N/A     N/A     N/A     106.355▲ N/A    
Latest Filters Detected On AIMS
RSI $AIMS RSI(14) Crossed Above 50 Set Alert
MA $AIMS Price Crossed Above MA(26) Set Alert
▲ BREAK $AIMS Price Breaks 10 Days High Set Alert
Acuitas Small Cap Active ETF News
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
Monday, March 02, 2026 06:00 AM
OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher ...
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
Monday, March 02, 2026 06:00 AM
OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher ...
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
Monday, February 23, 2026 05:55 AM
OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical ...
AIMS historical stock data
date open high low close volume
02/04/26 24.0199 24.06 23.88 24.0437 2,493
01/04/26 23.89 23.9399 23.88 23.9314 755
31/03/26 23.62 23.6876 23.62 23.6876 5,337
30/03/26 23.19 23.19 23.01 23.1458 6,814
27/03/26 23.42 23.42 23.3507 23.3507 179
26/03/26 23.73 23.77 23.645 23.645 9,635
25/03/26 23.95 23.9937 23.95 23.9937 3,771
24/03/26 23.80 23.89 23.80 23.8407 3,598
23/03/26 23.77 23.77 23.6982 23.6982 3,952
20/03/26 23.10 23.10 23.0854 23.0854 1,345
Quote Details
52wk Low:23.01
52wk High:25.137
Vol:2.49K
Avg Vol(3m):318.4K
1Y Chng:+0.00%
1M Chng:-4.00%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 0.00